Spiro Medical Raises $67M for Asthma Treatment Device
Spiro Medical, Inc. did not arrive with fireworks. It arrived with oxygen. Founded in 2024 in Irvine, California, this is a medtech company built around a simple but uncomfortable truth: severe asthma is not just an inflammatory problem, it is a neurological one. Instead of stacking another drug on an already exhausted patient, Spiro Medical, Inc. went upstream, into the spinal cord, and asked a better question about control, signaling, and breathing itself.
Pulmonary Neuromodulation sounds academic until you realize what it replaces. No daily inhalers. No injections on a calendar. No dependency disguised as maintenance. By adapting spinal cord stimulation to the T1, T5 region, Spiro Medical, Inc. targets the sympathetic pathways that actually regulate bronchial tone. It is not fighting symptoms, it is changing the conversation between the nervous system and the lungs. Less noise, more airflow.
On January 7, 2026, the company closed a $67M Series A, and this was not speculative capital chasing vibes. Andera Partners, Omega Funds, and Sherpa Healthcare Partners stepped in as co-leads with deep device, regulatory, and global scale DNA. HSG, Supernova Invest, Northern Light Venture Capital, and Hero Inc. Ltd UK rounded out a syndicate that knows how long real medtech takes and why it is worth the wait. Three new board seats followed, because conviction likes proximity.
The clinical data showed up before the applause. In a first-in-human study published in the Journal of Asthma, 91% of patients reduced medication use by more than 50%. 98% of asthma-only patients eliminated meds entirely. 100% reached well-controlled asthma with ACT scores above 19. Average ACT improvement was +13.3 points. Quality of life improved across the board. Zero exacerbations. Zero ER visits. Zero hospitalizations. Zero adverse events over 12 months. Eleven patients was enough to say this is signal, not coincidence.
Leadership is the difference between a clever idea and a durable company. Rinda Sama brings the Axonics operating discipline that scaled through FDA, public markets, and a $3.7B acquisition. Stephen T. Pyles brings 40+ years of neuromodulation and the clinical instincts that invented the tools others still use. Kurt Gehlsen brings regulatory fluency and translational precision. G. Jay Jiang brings the engineering rigor that makes implants safe, programmable, and long-lived. Raymond W. Cohen chairs the board with a track record that quietly terrifies timelines.
Asthma is a $27.46B global market dominated by pharmacology and habit. Severe asthma is 5-10% of patients and most of the cost, frustration, and sleepless nights. Spiro Medical, Inc. is not competing with inhalers, it is offering an exit ramp for patients who have already tried everything else and are done negotiating for breath.
Names matter. Spiro is not branding, it is physiology. Breathing is rhythm, neuromodulation is timing, and timing is everything. This company is early, deliberate, and technically dangerous in the right way. If you care about medtech that changes biology instead of slides, watch Spiro Medical, Inc. closely, because the quiet moments are usually when the lungs finally open.